Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-016452
Filing Date
2022-06-10
Accepted
2022-06-10 16:22:36
Documents
55
Period of Report
2022-04-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 985827
2 ex31-1.htm EX-31.1 18523
3 ex31-2.htm EX-31.2 19208
4 ex32-1.htm EX-32.1 7586
5 ex32-2.htm EX-32.2 8158
  Complete submission text file 0001493152-22-016452.txt   4413255

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anix-20220430.xsd EX-101.SCH 28817
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT anix-20220430_cal.xml EX-101.CAL 41839
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anix-20220430_def.xml EX-101.DEF 120725
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anix-20220430_lab.xml EX-101.LAB 250387
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anix-20220430_pre.xml EX-101.PRE 190215
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 777889
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 221009195
SIC: 2834 Pharmaceutical Preparations